Conceivably, normalisation of tumour vessels by bevacizumab-mediated blockade of VEGF may be more difficult to achieve and chemotherapeutic drugs cannot be delivered appropriately to the tumour cells when Ang-2 serum levels are high. Here, VEGFA is linked to neoplasm.